Patents Assigned to Epigenetics Ltd.
  • Bicyclic bromodomain inhibitors
    Patent number: 9663520
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 30, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 9636328
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 2, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Heterocyclic compounds as bromodomain inhibitors
    Patent number: 9598367
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 21, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young